Grazoprevir hydrate is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It functions as a potent inhibitor of the HCV NS3/4A protease, which is essential for viral replication. This compound is often combined with other antiviral agents, such as elbasvir, to enhance its efficacy and reduce the risk of resistance. The combination therapy is particularly effective against multiple HCV genotypes, offering a broad-spectrum antiviral solution. It is administered orally, providing a convenient treatment option for patients. Grazoprevir hydrate has shown significant success in achieving sustained virologic response (SVR), which is indicative of a cure for HCV infection. Its use has revolutionized HCV treatment by offering higher cure rates, shorter treatment durations, and fewer side effects compared to older therapies.